Trial Profile
A Global, Multi-center, Open-label, Phase 2 Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic PSCA-positive Pancreatic Cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Anti-PSCA monoclonal antibody (Primary) ; Gemcitabine
- Indications Pancreatic cancer
- Focus Therapeutic Use
- Sponsors Astellas Pharma
- 24 Jul 2012 Actual end date (Apr 2012) added as reported by ClinicalTrials.gov (Parent trial: NCT00902291).
- 01 Apr 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov (Parent trial: NCT00902291).
- 21 Dec 2011 Planned end date changed from 1 Oct 2011 to 1 Aug 2012 as reported by ClinicalTrials.gov.